Cangene Announces Agreement to Sell U.S. Plasma Centres

Transaction Supports Refocused Specialty Biopharmaceutical Strategy 
Readers are referred to the cautionary notes regarding Forward-looking 
Information at the end of this release. 
WINNIPEG, Sept. 17, 2012 /CNW/ - Cangene Corporation (Cangene) today announces 
that its wholly owned subsidiary, Cangene Plasma Resources, Inc. has entered 
into an agreement for the sale of its three U.S. based plasma centres to 
Grifols, through wholly owned Grifols subsidiary, Biomat USA, Inc. (Biomat 
USA). The transaction is expected to close in October, 2012 and is subject to 
customary closing conditions. The Company plans to reinvest the net sale 
proceeds in research and development programs and funding in-licensing 
Cangene will retain its Winnipeg-based plasma centre which is focused on 
collecting specialty plasma and plans to source its additional plasma needs 
from the open market, including through a supply agreement with Grifols. 
John A. Sedor, President and Chief Executive Officer of Cangene, said "The 
sale of our U.S. plasma centres is consistent with our refocused specialty 
biopharmaceutical strategy. With the previously announced cancellation of the 
IGIV program, we believe it makes more sense to source plasma primarily from 
the open market, rather than making the significant investment required to 
achieve scale and become a low-cost competitor in the highly competitive U.S. 
plasma collection industry. We believe that Cangene is now in a position of 
strength in the specialty biopharmaceutical space to expand the depth of its 
"Grifols is committed to ensuring a safe, reliable and consistent supply of 
source plasma for production of life-saving medicines," said Shinji Wada, 
President of Grifols Plasma Operations. "The acquisition of these centers 
further strengthens our existing plasma donation platform across the U.S. and 
reinforces our commitment to patients who depend on Grifols plasma-derived 
therapies". Currently, Grifols is a world-leader in plasma collection, with a 
network of 147 plasma donation centers in the United States that will enable 
the company to collect more than 6.5 million liters each year. 
Financial terms of the transaction were not disclosed. 
About Cangene Corporation
Cangene Corporation (TSX: CNJ), headquartered in Winnipeg, Canada, is one of 
the nation's oldest and largest biopharmaceutical companies. It is focused on 
the development and commercialization of hospital and oncology clinic based 
therapeutics. Cangene's products are sold worldwide and include products that 
have been accepted into the U.S. Strategic National Stockpile. Cangene has 
employees in three locations across North America. It operates manufacturing 
facilities in Winnipeg, Manitoba and Baltimore, Maryland (through its 
wholly-owned subsidiary, Cangene bioPharma, Inc.) where it produces its own 
products and undertakes contract manufacturing for a number of customers. For 
more information about Cangene, visit the Company's website at 
About Grifols
Grifols is a Spanish group, specializing in the hospital-pharmaceutical 
sector, and with a presence in over 100 countries. Since 2006, Grifols 
ordinary (Class A) shares have been listed on the Spanish Continuous Market 
and it has been included in the Ibex-35 (GRF) since 2008. Since 2011, 
non-voting Grifols shares (Class B) have also been listed on the Spanish 
Continuous Market (GRF.P) and on the NASDAQ (GRFS) via ADRs (American 
Depositary Receipts). Grifols has become the world's third largest producer of 
plasma derivatives by capacity following the recent purchase of Talecris and 
is the sector's largest European company, with a balanced and diverse range of 
products. The group will strengthen its position within the industry as a 
vertically integrated company, on the basis of its completed and additional 
planned investments. In terms of raw material, Grifols is the leading plasma 
collection company, with supplies assured via its network of 147 
plasmapheresis centers in the United States. Its production plants in Spain 
and the United States ensure that it has the fractionation capacity to satisfy 
rising demand. Geographic diversification is one of the key elements of the 
group's strategy for growth, and it has a major presence in the United States, 
Canada and Europe. For more information about Biomat USA or Grifols, please 
Cautionary Note regarding Forward-Looking Information
This document contains forward-looking statements about the Corporation, 
including its business operations, strategy, and expected financial 
performance and condition. Forward-looking statements include statements that 
are predictive in nature, depend upon or refer to future events or conditions, 
or include words such as "expects", "anticipates", "intends", "plans", "will", 
"believes", "estimates", or negative versions thereof, and similar 
expressions. In addition, any statement that may be made concerning future 
financial performance (including revenues, earnings or growth rates), ongoing 
business strategies or prospects, future use, safety and efficacy of 
unapproved products or unapproved uses of products, and possible future action 
by the Corporation are also forward-looking statements. Forward-looking 
statements are based on current expectations and projections about future 
events and are inherently subject to, among other things, risks, uncertainties 
and assumptions about the Corporation, economic factors and the 
biopharmaceutical industry generally. They are not guarantees of future 
performance. Actual events and results could differ materially from those 
expressed or implied by forward-looking statements made by the Corporation due 
to, but not limited to, important factors such as sales levels; fluctuations 
in operating results; the Corporation's reliance on a small number of 
customers including government organizations; the demand for new products and 
the impact of competitive products, service and pricing; the availability and 
cost of raw materials, and in particular, the cost, availability and antibody 
concentration in plasma; progress and cost of clinical trials; costs and 
possible development delays resulting from use of legal, regulatory or 
legislative strategies by the Company's competitors; uncertainty related to 
intellectual property protection and potential costs associated with its 
defence as well as general economic, political and market factors in North 
America and internationally; interest and foreign exchange rates; business 
competition; technological change; changes in government action, policies or 
regulations; decisions by Health Canada, the United States Food and Drug 
Administration and other regulatory authorities regarding whether and when to 
approve drug applications that have been or may be filed, as well as their 
decisions regarding labeling and other matters that could affect the 
availability or commercial potential of drug candidates; unexpected judicial 
or regulatory proceedings; catastrophic events; the Corporation's ability to 
complete strategic transactions; and other factors beyond the control of 
The reader is cautioned that the foregoing list of important factors is not 
exhaustive and there may be other factors listed in other filings with 
securities regulators, including factors set out under "Risk and 
Uncertainties" in the Corporation's Management Discussion and Analysis, which, 
along with other filings, is available for review at The reader 
is also cautioned to consider these and other factors carefully and not to 
place undue reliance on forward-looking statements. Other than as specifically 
required by applicable law, the Corporation has no intention to update any 
forward-looking statements, whether as a result of new information, future 
events or otherwise. 
Francis J. St.Hilaire Vice President, General Counsel & Secretary Ph: (204) 
SOURCE: Cangene Corporation 
To view this news release in HTML formatting, please use the following URL: 
CO: Cangene Corporation
ST: Manitoba
-0- Sep/17/2012 10:00 GMT
Press spacebar to pause and continue. Press esc to stop.